Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 102

1.

(31) P and (1) H MRS of DB-1 melanoma xenografts: lonidamine selectively decreases tumor intracellular pH and energy status and sensitizes tumors to melphalan.

Nath K, Nelson DS, Ho AM, Lee SC, Darpolor MM, Pickup S, Zhou R, Heitjan DF, Leeper DB, Glickson JD.

NMR Biomed. 2013 Jan;26(1):98-105. doi: 10.1002/nbm.2824. Epub 2012 Jun 29.

PMID:
22745015
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Mechanism of action of lonidamine in the 9L brain tumor model involves inhibition of lactate efflux and intracellular acidification.

Ben-Yoseph O, Lyons JC, Song CW, Ross BD.

J Neurooncol. 1998 Jan;36(2):149-57.

PMID:
9525814
[PubMed - indexed for MEDLINE]
3.

Enhancement of hyperglycemia-induced acidification of human melanoma xenografts with inhibitors of respiration and ion transport.

Zhou R, Bansal N, Leeper DB, Pickup S, Glickson JD.

Acad Radiol. 2001 Jul;8(7):571-82.

PMID:
11450957
[PubMed - indexed for MEDLINE]
4.

Metaiodobenzylguanidine and hyperglycemia augment tumor response to isolated limb perfusion in a rodent model of human melanoma.

Canter RJ, Zhou R, Kesmodel SB, Zhang Y, Heitjan DF, Glickson JD, Leeper DB, Fraker DL.

Ann Surg Oncol. 2004 Mar;11(3):265-73.

PMID:
14993021
[PubMed - indexed for MEDLINE]
5.

Noninvasive real-time monitoring of intracellular cancer cell metabolism and response to lonidamine treatment using diffusion weighted proton magnetic resonance spectroscopy.

Mardor Y, Kaplan O, Sterin M, Ruiz-Cabello J, Ash E, Roth Y, Ringel I, Cohen JS.

Cancer Res. 2000 Sep 15;60(18):5179-86.

PMID:
11016646
[PubMed - indexed for MEDLINE]
Free Article
6.
7.

Comparison of action of the anti-neoplastic drug lonidamine on drug-sensitive and drug-resistant human breast cancer cells: 31P and 13C nuclear magnetic resonance studies.

Vivi A, Tassini M, Ben-Horin H, Navon G, Kaplan O.

Breast Cancer Res Treat. 1997 Mar;43(1):15-25.

PMID:
9065595
[PubMed - indexed for MEDLINE]
8.

Bevacizumab-induced alterations in vascular permeability and drug delivery: a novel approach to augment regional chemotherapy for in-transit melanoma.

Turley RS, Fontanella AN, Padussis JC, Toshimitsu H, Tokuhisa Y, Cho EH, Hanna G, Beasley GM, Augustine CK, Dewhirst MW, Tyler DS.

Clin Cancer Res. 2012 Jun 15;18(12):3328-39. doi: 10.1158/1078-0432.CCR-11-3000. Epub 2012 Apr 10.

PMID:
22496203
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Thermal sensitisation by lonidamine of human melanoma cells grown at low extracellular pH.

Coss RA, Storck CW, Wells TC, Kulp KA, Wahl M, Leeper DB.

Int J Hyperthermia. 2014 Feb;30(1):75-8. doi: 10.3109/02656736.2013.858832. Epub 2013 Dec 3.

PMID:
24295212
[PubMed - indexed for MEDLINE]
10.

Lonidamine as a modulator of alkylating agent activity in vitro and in vivo.

Teicher BA, Herman TS, Holden SA, Epelbaum R, Liu SD, Frei E 3rd.

Cancer Res. 1991 Feb 1;51(3):780-4.

PMID:
1988117
[PubMed - indexed for MEDLINE]
Free Article
11.

Mechanism of action of the antineoplastic drug lonidamine: 31P and 13C nuclear magnetic resonance studies.

Ben-Horin H, Tassini M, Vivi A, Navon G, Kaplan O.

Cancer Res. 1995 Jul 1;55(13):2814-21.

PMID:
7796408
[PubMed - indexed for MEDLINE]
Free Article
12.

Effect of lonidamine on the cytotoxicity of four alkylating agents in vitro.

Rosbe KW, Brann TW, Holden SA, Teicher BA, Frei E 3rd.

Cancer Chemother Pharmacol. 1989;25(1):32-6.

PMID:
2590999
[PubMed - indexed for MEDLINE]
13.

Potentiation of anti-cancer drug activity at low intratumoral pH induced by the mitochondrial inhibitor m-iodobenzylguanidine (MIBG) and its analogue benzylguanidine (BG).

Kuin A, Aalders M, Lamfers M, van Zuidam DJ, Essers M, Beijnen JH, Smets LA.

Br J Cancer. 1999 Feb;79(5-6):793-801.

PMID:
10070871
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

TNF-alpha and melphalan modulate a specific group of early expressed genes in a murine melanoma model.

de Lima VC, de Carvalho AF, Morato-Marques M, Hashimoto VL, Spilborghs GM, Marques SM, Landman G, Torres C, Braga Ribeiro K, Brentani H, Reis LF, Dias AA.

Cytokine. 2013 May;62(2):217-25. doi: 10.1016/j.cyto.2013.02.022. Epub 2013 Mar 25.

PMID:
23534980
[PubMed - indexed for MEDLINE]
Free Article
15.

Metabolic alterations in implanted human tumors after combined radiation and hyperthermia therapy measured by in vivo 31P MRS.

Kimura H, Itoh S, Kawamura Y, Nakatsugawa S, Ishii Y.

Magn Reson Imaging. 1994;12(1):109-19.

PMID:
8295498
[PubMed - indexed for MEDLINE]
16.

Optimizing radiotherapy of brain tumours by a combination of temozolomide & lonidamine.

Prabhakara S, Kalia VK.

Indian J Med Res. 2008 Aug;128(2):140-8.

PMID:
19001677
[PubMed - indexed for MEDLINE]
18.

The effect of lonidamine (LND) on radiation and thermal responses of human and rodent cell lines.

Raaphorst GP, Feeley MM, Danjoux CE, Martin L, Fisher B, Maroun J, DeSanctis AJ.

Int J Radiat Oncol Biol Phys. 1991 Mar;20(3):509-15. Erratum in: Int J Radiat Oncol Biol Phys 1991 Jul;21(2):533.

PMID:
1995536
[PubMed - indexed for MEDLINE]
19.

Impact of hyperthermic regional perfusion therapy on cell metabolism of malignant melanoma monitored by 31P MR spectroscopy.

Semmler W, Gademann G, Schlag P, Bachert-Baumann P, Zabel HJ, Lorenz WJ, von Kaick G.

Magn Reson Imaging. 1988 May-Jun;6(3):335-40.

PMID:
3398741
[PubMed - indexed for MEDLINE]
20.

Optimizing the factors which modify thermal enhancement of melphalan in a spontaneous murine tumor.

Mohamed F, Stuart OA, Glehen O, Urano M, Sugarbaker PH.

Cancer Chemother Pharmacol. 2006 Dec;58(6):719-24. Epub 2006 Apr 14.

PMID:
16614851
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk